Met-Enkephalin Peptides Met5

Met-enkephalin is an endogenous pentapeptide neurotransmitter naturally produced in the mammalian central nervous system. Met-Enkephalin Powder is the synthetic solid powder form of this peptide with high chemical purity.

Basic Properties

Chemical Name: L-Tyrosylglycylglycyl-L-phenylalanyl-L-methionine

Amino Acid Sequence: Tyr-Gly-Gly-Phe-Met

Physical Form: White or off-white crystalline lyophilized powder, soluble in water and dilute acidic solutions, poorly soluble in organic solvents.

Storage Condition: Sealed storage under low temperature (-20°C), protected from light and moisture to avoid peptide degradation.

Main Applications

Scientific Laboratory Research Material It is widely used in neuropharmacology, pain mechanism research, neuroscience and immunology experiments. Researchers use this powder to prepare peptide solutions for cell incubation, animal model administration and receptor binding assays.

Peptide Raw Material for Biochemical Study It serves as a standard reference substance for opioid receptor testing and endogenous neuropeptide quantitative analysis.

Preclinical Pharmaceutical Study It is studied as a lead compound for developing non-addictive analgesic peptide drugs, exploring novel pain treatment formulations.

Product Specifications

Lab-grade Met-Enkephalin Powder normally has a purity ≥98% tested by HPLC, with low peptide impurity content and negligible endotoxin levels for cell and animal experiments.

Important Note

This peptide powder is strictly limited to laboratory scientific research use only. It is not approved for human injection, oral administration or clinical treatment, and cannot be used as a pharmaceutical raw material for finished drugs without official drug approval.

Met-enkephalin acts as an endogenous opioid ligand that selectively binds to mu and delta opioid receptors located on neuronal cell membranes. It inhibits the release of substance P and other pain-signaling neurotransmitters, blocks the transmission of nociceptive nerve impulses in the spinal cord and brain, and generates natural analgesic effects without the high addiction risk of chemically synthesized opioid narcotics. It also participates in regulating immune activity, emotional response and neuroendocrine balance.

1.Analgesic Effect Met-enkephalin is an endogenous opioid peptide. It binds specifically to delta and mu opioid receptors in the nervous system. It suppresses the secretion of pain-transmitting neurotransmitters and intercepts pain signal conduction, producing significant pain-relief activity.

2.Immunomodulatory Function This peptide can regulate the proliferation and activity of immune cells including lymphocytes and macrophages. It mediates the interaction between the nervous system and the immune system, adjusting the body's immune response.

3.Neuroregulation It participates in the regulation of neural excitability, mood, stress response and neuroendocrine secretion in the brain. It plays a key role in studying nervous system signal transmission.

4.Research Application Function As a purified lyophilized powder, it is prepared into stock solutions for laboratory experiments. It is commonly applied in receptor binding tests, cell culture assays, animal model studies, and neuropeptide quantitative detection as a standard research reagent.

5.Preclinical Drug Research Value Scientists take Met-enkephalin as the parent compound to develop low-addiction analgesic peptide medicines, overcoming the dependence problem caused by traditional opioid painkillers.

Important Precondition

Met-Enkephalin powder is strictly a laboratory research reagent, not an approved clinical drug. All dosage data below are only for in vitro cell experiments and animal model research, not for human administration.

1. In Vitro Cell Culture Dosage

Working concentration range: 1 nM – 10 μM

Common experimental concentration: 100 nM to 1 μM

Preparation: Dissolve the powder in sterile water or PBS buffer to make a concentrated stock solution, then dilute to the target concentration in cell culture medium.

2. In Vivo Animal Administration Dosage (Mice & Rats)

Intravenous (IV) Injection

Daily dose: 0.5 mg/kg – 5 mg/kg of body weight

Intracerebroventricular (ICV) Injection (central nervous system study)

Single dose: 1 μg – 10 μg per individual rodent

Intraperitoneal (IP) Injection

Daily dose: 2 mg/kg – 8 mg/kg

3. Preparation Notes

Make fresh peptide solution right before use to prevent degradation.

Avoid repeated freeze-thaw cycles of the prepared stock solution.

Filter the solution with a 0.22 μm filter for sterile cell and animal experiments.

Disclaimer

This peptide cannot be used for human injection, oral use or clinical therapy. Improper dosage will lead to nervous system disorder and other physiological risks.

Important note: This substance is only for laboratory scientific research. No clinical human usage data is available. All side effects summarized below are observed from animal experiments and in-vitro studies.

1. Nervous System Reactions

Temporary inhibition of nerve excitability. Excess dosage may cause slow movement, lethargy and reduced activity in experimental animals.

Short-term respiratory depression at ultra-high doses, which is a typical opioid-related reaction.

Disturbance of neuroendocrine secretion, affecting the release of stress-related hormones.

2. Gastrointestinal Reactions

High-dose administration slows gastrointestinal peristalsis, leading to reduced food intake, constipation and digestive dysfunction in animal subjects, consistent with the characteristics of opioid peptides.

3. Dependence and Tolerance Risk

Long-term continuous administration will gradually generate drug tolerance. Repeated use may produce mild physical dependence, just like other endogenous opioid substances. Once the supply stops, mild withdrawal reactions may appear.

4. Immune Function Changes

Abnormally high concentrations may excessively suppress or activate immune cell activity, breaking the balance between nerve and immune systems and causing irregular immune responses.

5. Local Irritation

If injected subcutaneously or intraperitoneally, the peptide solution may cause slight local tissue irritation when the concentration is too high.

6. Other Precautions

Degraded Met-Enkephalin loses biological activity and may produce peptide impurities that trigger nonspecific reactions.

No reliable safety data for human oral, injection or skin application. Unauthorized use on humans will bring unpredictable risks to the central nervous system and internal organs.

Disclaimer

Met-Enkephalin powder is strictly limited to laboratory research only. It is not a finished pharmaceutical product. Any off-label use on humans or livestock is prohibited.

Disclaimer: Met-Enkephalin powder is solely a laboratory research peptide, not an approved therapeutic drug. All information below is based on preclinical pharmacological research for experimental reference only, and it is not applicable to human clinical medication.

Other opioid receptor agonists (prohibited combined use) Co-administration with morphine, fentanyl, oxycodone, and other synthetic opioids creates synergistic central inhibitory effects. This combination drastically raises the risk of severe respiratory depression, bradycardia, circulatory collapse, and deep sedation. It also accelerates the onset of drug tolerance and physical dependence.

Central nervous system depressants Sedatives, hypnotics, barbiturates, benzodiazepines, general anesthetics, and ethanol amplify the neuroinhibitory effect of Met-Enkephalin. Concurrent administration leads to excessive drowsiness, slowed reflexes, and life-threatening respiratory suppression in animal models. This combination must be avoided in all in vivo experiments.

Monoamine oxidase inhibitors (MAOIs) MAOIs slow down the enzymatic breakdown of neuropeptides. When used together with Met-Enkephalin, peptide levels in the central nervous system build up excessively, resulting in unregulated neuroendocrine activity and erratic experimental outcomes.

Immunomodulating drugs Met-Enkephalin naturally modulates lymphocyte and macrophage function. When paired with immunosuppressants or immunostimulants, the two substances produce overlapping immune regulation, causing unbalanced immune responses and inconsistent experimental data.

Calcium channel blockers These agents alter neurotransmitter release from nerve endings. Joint application changes the pain-modulating potency of Met-Enkephalin and destabilizes receptor binding test results.

Chemical incompatibilities (for solution preparation)

Do not mix with alkaline buffers, which trigger peptide hydrolysis and loss of biological activity.

Avoid mixing with solutions containing heavy metal ions, which bind to the peptide structure and deactivate it.

Final Warning

Human administration of this peptide, especially combined with any prescription drugs, carries severe life-threatening risks. This product is restricted strictly to in vitro cell assays and animal research only.

Common Side Effects

Cardiovascular reactions: Transient hypotension, flushing, tachycardia. These usually occur shortly after administration and are mild and reversible.

Gastrointestinal symptoms: Nausea, vomiting, abdominal distension and mild diarrhea.

Local reactions: Redness, swelling or soreness at the injection site for parenteral use.

Less Common Side Effects

Respiratory discomfort: Mild cough, transient shortness of breath.

Systemic symptoms: Dizziness, fatigue, headache.

Metabolic changes: Slight decrease in blood glucose in individual patients.

Rare but Severe Adverse Reactions

Severe hypotension: May lead to syncope, especially in patients with unstable cardiovascular conditions.

Hypersensitivity reactions: Rash, urticaria, pruritus; very rarely anaphylaxis.

Severe gastrointestinal disturbances: Severe vomiting or persistent abdominal pain.

Special Notes

Side effects are generally dose-related. Adverse reactions are more likely to appear if the infusion rate is too fast or the dose is excessive.

Patients with pre-existing heart disease, hypotension or gastrointestinal disorders need close monitoring during medication.

Any persistent or severe discomfort must be reported to medical staff immediately.

Other Nootropics Raw Material Also Available

Delivery Time:Around 3-5 workdays after your payment.

Package:1kg/aluminium foil bag;25Kgs in fiber-drums with two-plastic bags inside

Net Weight:25kgs/Drum/Gross Weight:28kgs/Drum

Drum Size & Volume:I.D.42cm × H52cm,0.08 m³/Drum

Storage:Stored in dry and cool place,keep away from strong light and heat.

Shelf Life:Two years when properly stored.

Hot Tags: met-enkephalin peptides met5, China met-enkephalin peptides met5 manufacturers, suppliers, factory, Dihexa for Memory Enhancement, High Purity Pantethine, Larazotide for Digestive Health Supplement, Loratadine for Skin Allergies, Loratadine Raw Powder, Tetrahydrocurcumin for Skin Health